Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Decrease of cyclin D1 in the human lung adenocarcinoma cell line A-427 by 7-hydroxycoumarin.

F A Jiménez-Orozco1, J S López-González, A Nieto-Rodriguez

  • 1Departamento de Farmacología, Facultad de Medicina, Universidad Nacional Autónoma de México, Apdo. Postal 70-297 Ciudad Universitaria, Mexico D.F. 04510, Mexico. alejo@servidor.unam.mx

Lung Cancer (Amsterdam, Netherlands)
|October 27, 2001
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Alchemical free energy-based optimization of quinazoline derivatives as potent EGFR inhibitors with cytotoxic activity.

Bioorganic & medicinal chemistry·2025
Same author

The non-vesicle cell-free DNA (cfDNA) induces cell transformation associated with horizontal DNA transfer.

Molecular biology reports·2024
Same author

Insights into toxicology, safety pharmacology, and drug dependence testing: The performance and predictive values of nonclinical tests.

Journal of pharmacological and toxicological methods·2020
Same author

Guillain-Barré syndrome and influenza vaccines: current evidence.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2019
Same author

Extensive preclinical evaluation of an infliximab biosimilar candidate.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2017
Same author

Expansion of quiescent lung adenocarcinoma CD8+ T cells by MUC1-8-mer peptide-T2 cell-β2 microglobulin complexes.

Oncology reports·2015

7-hydroxycoumarin, a coumarin metabolite, inhibits lung cancer cell proliferation by impacting the cell cycle and decreasing cyclin D1 expression, suggesting potential therapeutic applications.

Area of Science:

  • Biochemistry and Molecular Biology
  • Pharmacology and Toxicology
  • Cancer Research

Background:

  • Coumarin exhibits antitumor activity in various cancers.
  • 7-hydroxycoumarin, a human metabolite of coumarin, also shows in vitro anti-proliferative effects on tumor cells.
  • The precise molecular mechanisms underlying these anticancer effects remain largely unknown.

Purpose of the Study:

  • To investigate the molecular mechanisms of coumarin and 7-hydroxycoumarin in inhibiting human lung adenocarcinoma cell line A-427.
  • To assess the impact of these compounds on cell proliferation, cell cycle progression, and the expression of cyclins D1, E, and A.

Main Methods:

  • Cytostatic assays (MTT reduction) were used to determine inhibitory concentrations 50 (IC50).
  • Cell cycle progression was analyzed using propidium iodide and BrdU with DNA histograms and multiparametric flow cytometry.

Related Experiment Videos

  • Cyclin D1, E, and A expression levels were quantified via bivariate flow cytometry and RT-PCR for cyclin D1 mRNA.

    • Main Results:

    • 7-hydroxycoumarin demonstrated significant cytostatic effects with an IC50 of 100 µg/ml at 72h exposure, inhibiting G1/S cell cycle transition.
    • 7-hydroxycoumarin significantly decreased cyclin D1 expression, suggesting an effect on early G1 phase events, potentially via posttranscriptional regulation.
    • Coumarin showed non-significant effects, and neither compound significantly altered cyclin E or A expression.

    Conclusions:

    • 7-hydroxycoumarin effectively inhibits lung adenocarcinoma cell proliferation by modulating cell cycle progression and downregulating cyclin D1.
    • The observed decrease in cyclin D1, without a change in its mRNA, indicates a posttranscriptional inhibitory mechanism for 7-hydroxycoumarin.
    • Targeting cyclin D1, which is overexpressed in many cancers, with compounds like 7-hydroxycoumarin presents a promising avenue for novel cancer therapies.